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Abstract
Background: Alpha-tocopheryloxyacetic acid (α-TEA) is a semi-synthetic derivative of naturally occurring vitamin
E (alpha-tocopherol) that can be delivered via an oral route. Preclinical in vitro and in vivo data demonstrated that
α-TEA is a potent anti-tumor agent with a safe toxicity profile in mice. We report a comprehensive study to evaluate
the toxokinetics of good manufacturing practice (GMP)-grade α-TEA in dogs after daily oral administration for 28 days,
followed by a 28-day recovery period.
Methods: Male and female beagle dogs received capsules of α-TEA Lysine Salt at doses of 100, 300, 1500 mg/kg/day.
α-TEA plasma levels were determined by high-performance liquid chromatography (HPLC) with mass spectrometric
detection. During the treatment, animals were observe for clinical signs, food consumption, body weight, and
subjected to ophthalmoscopic, and electrocardiographic assessments. At the end of the dosing period, blood
was taken and toxicokinetic analyses and histopathology assessments were performed when animals were
necropsied.
Results: Our findings showed that there was no α-TEA-related mortality or moribundity. At the highest dose,
increases in white blood cells and fibrinogen levels were observed. These levels returned to normal at the end
of the recovery period. Histopathological evaluation of major organs revealed no significant lesions related to
α-TEA-treatment.
Conclusion: We demonstrate that for designing clinical trials in patients, the highest non-severely toxic dose
(HNSTD) of α-TEA is 1500 mg/kg/day in Beagle dogs and this data informed the design of dose-escalation
studies of α-TEA in patients with advanced cancer.
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Background
Alpha-tocopheryloxyacetic acid (α-TEA) is a semi-synthetic,
non-hydrolysable ether derivative of vitamin E. Structur-
ally, α-TEA differs from vitamin E by the replacement of
the hydroxyl group at the carbon number 6 of the phen-
olic ring of the chroman head with an acetic acid residue
linked by an ether bound [1]. α-TEA is a cytotoxic drug
that induces tumor cell death through targeting the mito-
chondria and by modulation of apoptosis and survival
pathways [2]. The in vivo anti-tumor activity of α-TEA
has been reported in several pre-clinical tumor models
[1], and is partially dependent on a T-cell-mediated im-
mune response [3–6]. Although α-TEA has been evalu-
ated as an anti-cancer agent in numerous pre-clinical
tumor models [1, 7–10], efforts to translate these find-
ings into human clinical trials are lacking. The goal of
this study was to conduct a dose-escalation evaluation
in an appropriate non-rodent animal species as re-
quired by the United States Food and Drug Administra-
tion (U. S. FDA) to obtain relevant toxico- and
pharmaco-kinetic information in preparation for a first-in-
human trial to evaluate the safety and tolerability of α-
TEA in patients with advanced cancer. α-TEA lysine salt
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was administered at increasing doses of 100, 300 and
1500 mg/kg to male and female beagle dogs for 28 con-
secutive days, and then observed for 28 days after the last
α-TEA dose. Complete measurements of body weight and
food consumption were conducted over the treatment
period. Ophthalmologic and electrocardiographic observa-
tions were assessed and clinical pathology evaluated. In
this dose escalation study utilizing the lysine salt of α-
TEA, we demonstrated that daily administration of α-TEA
was not toxic at 1500 mg/kg body weight. The findings
from this comprehensive and observational study to
evaluate the pharmacology and toxicology of the α-
TEA (lysine salt) in beagle dogs formed the basis for
initiating a first-in-human clinical trial in patients with
advanced cancer that is ongoing (NCT 02192346).
Methods
Preparation of α –Tocopheryloxyacetic acid lysine salt in
capsules
In the process of manufacturing α-TEA free acid for
pre-clinical development, the contract Commercial Re-
search Organization (Ricerca Biosciences, LLC, Concord
OH) made the observation that during the initial scale-
up, the free acid exhibited liquid crystal properties.
Therefore, a salt screen was performed, which led to the
identification and selection of the lysine salt. α-TEA
lysine salt (α-TEA LS) was synthesized (Fig. 1), using a
modification of a previously described procedure [9].
Briefly, α-TEA LS was prepared by reacting alpha-D-
tocopherol with ethyl bromoacetate to form the ethyl
ether intermediate. The ethyl ether intermediate was
then reacted with potassium hydroxide to form α-TEA
free acid. The lysine salt was formed by adding aque-
ous lysine solution to a solution of α-TEA in isopropyl
alcohol. The lysine salt with its empirical formula of
C37H66N2O6 and its molecular weight of 634.93 g/mol
is a stable crystalline off-white powder. The dose con-
centration analysis was performed during the study
and the test material was stable. Capsules for oral dose
administration were prepared at least once weekly
with appropriate amounts of bulk α-TEA placed into
gelatin capsules (Pharmatek LLC, San Diego CA). Oral
administration is the planned route of administration
in humans. The dose of the drug is expressed as free acid
using a correction factor of 1.3 to reflect salt content (cal-
culated as ratio of lysine salt/free acid molecular weight).
Animal studies
Initial studies in mice were conducted to assess the effi-
cacy of the lysine salt form of α-TEA against established
tumors. Treatment of the animals (including but not
limited to all husbandry, housing, and feeding condi-
tions and euthanasia) was conducted in accordance
with The Animal Welfare Act (Public Law 89-544)
and the guidelines recommended in Guide for the Care
and Use of Laboratory Animals (National Academy
Press, Washington DC, 2011). The protocols and
procedures involving the care and use of animals in
Fig. 1 Chemical structure of α-Tocopherol, α-Tocopheryloxy Acetic Acid (α-TEA), and α-tocopheryloxy acetic acid Lysine Salt (α-TEA LS).
a α-Tocopherol. Molecular Weight (MW) = 430.69. b α-Tocopheryloxy Acetic Acid (α-TEA). MW = 488. c α-TEA Lysine Salt. MW = 634.93
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the study were reviewed and approved by the Earle A.
Chiles Research Institute and Ricerca Institutional
Animal Care and Use Committees (IACUC).
α-TEA was formulated in mouse chow and delivered
to mice bearing established 4 T1 mammary tumors, as
we previously described. This anti-tumor study was
followed by a toxicology study. For this purpose, both
the α-TEA free acid and α-TEA LS forms were adminis-
tered to naïve mice intravenously or by oral gavage. A
total of 44 Beagle dogs (Canis familiaris; were acquired
by the contract CRO (Ricerca Biosciences) from Marshall
BioResources, North Rose, NY) for the study. Animals
were as uniform in age as possible; dogs were pre-pubertal
to young adults, at least 8 months of age (range of 7.8 to
8.3 months of age) and weighed between 4 and 8 kg at the
start of dose administration. The frequency of administra-
tion was designed to mimic the regimen intended for hu-
man trial. α-TEA LS was administered in gelatin capsules
once daily to 22 male and 22 female dogs at 100, 300 and
1500 mg/kg for 28 consecutive days. The amount for each
animal was based on the most recent body weight. Control
animals received equal number of empty gelatin capsules
as the high dose animals. Animals were observed for
viability and clinical signs, daily food consumption,
body weight (once weekly or twice for high dose animals).
Group assignment and dose level are shown in the Table 1.
Clinical pathology, ophthalmic and electrocardiography
examinations were done at the pre-dose and after the
terminal dose. Eight dogs from each group (4 females
and 4 males) were necropsied at the end of the dosing
period (Day 29) or at the end of the recovery period
(Day 57). Animals were fasted overnight prior to sched-
uled blood test or necropsy. When necropsied, organs
were collected and preserved in 10 % neutral-buffered
formalin with the exception of the testes, epididymides,
and eyes; which were fixed in Modified Davidson’s
Solution for 24 to 48 h, water washed, and then
transferred to 10 % neutral-buffered formalin for storage.
Histopathology assessments were performed. Bone mar-
row smears were stained with Wright-Giemsa before
cytology evaluation.
Toxicokinetics studies
Toxicokinetics studies were performed by Celerion Inc.,
a commercial research organization based in Lincoln,
Nebraska, USA. Toxicokinetic parameters were studied
on blood collected from the jugular vein of the animal
(1 mL) on day 1 and on the last day of treatment. Blood
samples were collected into K3EDTA-containing tubes at
1, 2, 4, 8, and 24 h following the first α-TEA administra-
tion. Following the last administration (day 28), blood
collection for recovery animals was scheduled as follows:
2, 8, 24, 72, and 168 h. For the control animals (group
1), only the 8-hour sample was collected. The chosen
time points were based on kinetic data gathered from
pilot toxicity studies conducted in mice. Recovered
plasma was stored at -70 °C until analysis.
Data collection
Animal data, such as observations, body weights, food
consumption, clinical pathology values, necropsy find-
ings, and organ weights, were collected and reported
electronically using Provantis™, Version 8 (Instem LSS
Ltd. Staffordshire, UK). Urine was collected and analyzed
by a Clinitek Atlas Urinalysis System. Data from the exam-
ination of urine sediment were entered directly into
ProvantisTM. Toxicokinetics data were collected and stored
in electronic notebook system LabnotesTM Client 1.18.
Sample preparation and High Performance Liquid
Chromatography (HPLC) analysis
Systemic levels of α-TEA were determined using HPLC
with mass spectrometry. Bioanalytical data were ob-
tained from Celerion, Inc according to the SOPs written
based on the GLP principles. Briefly, an aliquot of the
extracted dog plasma was analyzed by an HPLC
equipped with an AB SCIEX API 4000TM triple quadrupole
mass spectrometer using an ESI source. Negative ions were
monitored in the multiple reaction-monitoring (MRM)
mode. Quantitation was determined using a weighted linear
regression analysis (1/concentration2) of peak area
ratios of the analyte and internal standard. The area
under the plasma concentration-time curves, peak
Table 1 Group assignment and dose levels
Group Number of animals (M/F) Test article Nominal dose level (mg/kg/day) Actual dose levela Number of animals for necropsy (M/F)
Terminal (Day 29) Recovery (Day 57)
1 6/6 Vehicle 0 0 4/4 2/2
2 4/4 α-TEA 100 130 4/4 -
3 6/6 α-TEA 300 390 4/4 2/2
4 6/6 α-TEA 1500 1950 4/4 2/2
aDose levels have been corrected for lysine salt using a correction factor of 1.3
A total of 44 Beagle dogs (22 males and 22 females) received α-TEA lysine salt at different concentrations (0, 100, 300, 1500 mg/kg). Eight dogs from each group
(4 females and 4 males) were necropsied at the end of dosing period (Day 29) or at the end of recovery period (Day 57)
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plasma concentration, time to achieve peak plasma
concentration, and plasma terminal half-life (AUC,
Cmax, Tmax, and T1/2) were determined using WinNonlin
Version 6.2 (Pharsight, Mountain View CA), operating as
a validated software system.
Statistical analysis
For comparative statistics, data through the Day 29
termination were evaluated using the Levene Test for
homogeneity of variances and the Shapiro-Wilks Test
for normality of distributions, with significance at p ≤ 0.05.
Data determined to be homogeneous and of normal distri-
bution were evaluated for analysis of variance (ANOVA).
If the ANOVA verified significance at p ≤ 0.05, pairwise
comparisons of each treated group with the control group
were made using a parametric test, Dunnett t-test, to iden-
tify statistical differences (p ≤ 0.05). Data determined to be
nonhomogeneous or of non normal distribution were
evaluated using a Kruskal-Wallis Test for group factor sig-
nificance. If significance (p ≤ 0.05) existed between groups,
a nonparametric test, Wilcoxon with Bonferroni-Holm,
was used to compare treated groups to the control group.
Results
Anti-tumor activity of α-TEA lysine salt
We first tested the anti-tumor activity of GMP-
manufactured α-TEA LS, by conducting experiments
in BALB/c mice bearing established 4 T1 mammary
tumors as previously described [11]. Tumor bearing
mice received (i) control diet until 5 days post-tumor
cell injection, and then were switched to 0.39 % α-
TEA salt diet; or (ii) 390 mg/kg body weight α-TEA
LS diet. After 60 days of tumor monitoring, we found
that α-TEA LS significantly inhibit tumor growth
(Fig. 2a) and prolonged overall survival compared to
control diet (Fig. 2b). Blood samples were collected
from 3 naïve mice/group and systemic levels of α-TEA
were determined by HPLC with mass spectrometry de-
tection in order to compare the pharmacokinetics and
exposure of a single dose of α-TEA LS with that of the
Fig. 2 Anti-tumor activity of α-TEA lysine salt. a Effect of dietary delivery of α-TEA lysine salt on primary tumor growth. BALB/c mice were injected
with 5x104 4 T1 tumor cells in the right mammary fat pad. When tumors became palpable (~5 days post tumor cell injection) mice received
390 mg/kg/day α-TEA lysine salt diet (equivalent to 300 mg/kg/day α-TEA) and tumor growth was monitored. b Oral α-TEA lysine salt prolongs
survival of mammary tumor-bearing mice. BALB/c with established 4 T1 mammary tumors (day 5, ~ 4-6 mm2) received oral α-TEA lysine salt diet
(390 mg/kg bodyweight) or nutrient-matched control diet. Mantel-Cox analysis of survival of n = 8 mice per group
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free acid. The free acid could only be administered by
gavage because it was toxic when administered by
intravenous injection. However, both routes of admin-
istration could be used with the lysine salt. As shown
in Fig. 3 and Table 2, when α-TEA was administered
orally by gavage at the same dose level (200 mg/kg),
exposure was higher with α-TEA LS compared to α-
TEA free acid. The peak plasma concentration after
administration (Cmax) was 2 times higher with α-TEA
LS compared to the α-TEA free acid (Fig. 3). We ob-
served a saturation phenomenon reflected by a slight
decrease in Cmax following the increase in dose level
from 100 mg/kg to 200 mg/kg of α-TEA free acid
(Table 2). Our data indicate that the time to reach the
peak plasma concentration after administration (Tmax)
is 4 h with α-TEA LS versus 24 h for α-TEA free acid.
The elimination half-lives was similar between 100
and 200 mg/kg α-TEA free acid and 200 mg/kg α-TEA
lysine salt (54.6/50.2/54.6 h respectively).
Repeat daily dosing of α-TEA Lysine Salt did not cause
gross toxicity
Several experiments were performed to evaluate the
pharmacology and toxicology profile of repeated dosing
of GMP-grade α-TEA LS in Beagle dogs, over a period
of 28 days followed by a 28-day recovery period. Dose
levels were chosen based on available data in mice [11]
and from a preliminary dog tolerability study. Once
daily, α-TEA salt was administered in gelatin capsules to
male and female Beagle dogs at 100, 300 and 1500 mg/kg
body weight for 28 consecutive days. Clinical signs were
limited to fecal changes (decreased/discolored) and emesis
in 1500 mg/kg animals on several occasions following start
of dose administration and continuing until the start of re-
covery period. The decreased feces coincided with transi-
ent decreases in food consumption noted in several
animals, and persisted upon continued dosing. α-TEA ef-
fects on food consumption at 1500 mg/kg were also
reflected in the slightly decreased in body weight gain in
Fig. 3 Exposure of BALB/c mice to a single-dose of lysine salt or free acid α-TEA. α-TEA free acid (100 mg/kg) and α-TEA lysine salt (200 mg/kg)
were administered by intravenous injection or oral gavage. Blood was collected from 3 mice/group at each time point and analyzed for α-TEA
levels by high performance liquid chromatography (HPLC) with mass spectrometric detection (LC-MS/MS)
Table 2 Effect of a single dose of α-TEA lysine salt or free acid on serum pharmacokinetics parameters
Test article Dose level (mg/kg) Tmax (hr) T½ (hr) Cmax (ug/mL) AUC0-24 (hr*ug/mL) AUC0-∞ (hr/*ug/mL)
α-TEA Free Acid 100 8 54.6 20.4 1,180 1,670
α-TEA Lysine Acid 200 4 54. 29.4 1,680 2,470
α-TEA Free Acid 200 24 50.2 14.7 1,020 1,400
α-TEA free acid (100 mg/kg) and α-TEA lysine salt (200 mg/kg) were administered by intravenous injection or oral gavage in BALB/c mice. Blood was collected
from 3 mice/group at each time point and analyzed for α-TEA levels by HPLC with mass spectrometric detection (LC-MS/MS). The peak plasma concentration of a
drug after administration (Cmax), the time required to reach it (Tmax), the time required for the concentration of the drug to reach half of its original value (T1/2),
the area under the plasma drug concentration-time curve (AUC) were determined using WinNonlin Version 6.2 software system
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all 1500 mg/kg males during the second and third week of
dose administration and in two of six females during the
second week and all the 1500 mg/kg females during the
third week of administration (Fig. 4a, b). Individual body
weight gain decreases were present at 300 and 100 mg/kg;
however, overall group mean was comparable to controls
and the changes were not considered toxicologically
relevant. During the recovery period, the body weight
gain in control and α-TEA-treated animals was compar-
able (data not shown). There was no moribundity or mor-
tality throughout the course of treatment. There were no
α-TEA-related ophthalmologic findings, but the 1500 mg/
kg group showed sinus bradycardia on electrocardiograms
at day 27 for the males and day 26 for the females.
Clinical pathology (erythroid, leukocytes, coagulation
parameters, serum chemistry and urinalysis) of α-TEA-
treated animals
At the dosing level of 100, 300, and 1500 mg/kg, no effect
on erythroid or serum chemistry was observed. On day
29, white blood cell counts (neutrophils and lymphocytes)
and fibrinogen levels were slightly higher in animals that
received 1500 mg/kg α-TEA LS (in 2 of 4 males and 2 of 4
females) compared to their pre-dose level (Tables 3 and 4).
Interestingly, at the end of the recovery period, no α-TEA-
related changes in coagulation or leukocyte parameters
were recorded (Tables 5). On Day 29, evaluation of serum
chemistry parameters showed that the mean chloride con-
centration (CL), mean blood urea nitrogen concentration
Fig. 4 Measure of body weights during 28-day dosing of α-TEA lysine salt. Male (a) and female dogs (b) received indicated doses of α-TEA lysine salt
daily. Body weights were determined twice before the start of the treatment and every week following the start of the treatment. Data points represent
mean body weight ± SD
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Table 3 Mean blood cells and coagulation parameters in dogs 10 days prior to treatment
Vehicle 100 mg/kg 300 mg/kg 1500 mg/kg Unit
Mean SD N Mean SD N Mean SD N Mean SD N
Males Erythrocytes
Red blood cells 6.315 0.485 6 6.418 0.316 4 6.523 0.211 6 6.74 0.416 6 M/ul
Hemoglobin 13.98 1.13 6 13.83 0.71 4 14.43 0.48 6 14.8 1.21 6 g/L
Hematocrit 43.18 3.51 6 43.08 1.54 4 44 1.5 6 45.23 3.2 6 %
Mean corpuscular volume 63.38 0.97 6 67.18 1.55 4 67.52 2.46 6 67.1 1.42 6 fL
Mean corpuscular hemoglobin 22.1 0.3 6 21.58 0.62 4 22.12 0.78 6 21.95 0.76 pg
Mean corpuscular hemoglobin concentration 32.37 0.18 6 32.13 0.61 4 32.73 0.2 6 32.73 0.56 6 g/dL
Reticulocytes 24.63 13.54 6 29.25 7.68 4 22.28 5.7 6 21.75 10 6 109/L
Leukocytes
White blood cells 7.473 1.869 6 7.373 1.858 4 9.175 2.951 6 7.103 1.64 6 K/uL
Neutrophils 1.207 1.602 6 3.9 1.37 4 5.428 2.489 6 3.943 1.249 6 K/uL
Lymphocytes 2.473 0.55 6 2.69 0.506 4 2.638 0.788 6 2.445 0.445 6 K/uL
Monocytes 0.512 0.275 6 0.54 0.083 4 0.668 0.413 6 0.375 0.121 6 K/uL
Eosinophils 0.128 0.077 6 0.14 0.022 4 0.282 0.171 6 0.193 0.108 6 K/uL
Basophils 0.093 0.051 6 0.063 0.021 4 0.09 0.029 6 0.082 0.018 4 K/uL
Thrombocytes
Platelets 381.7 39.4 6 330.8 80.1 4 427.8 82.2 6 360 57.4 6 K/uL
Mean platelet volume 12.38 1.52 6 14.28 2.15 4 12.62 1.17 6 13.53 0.9 6 fL
Protrombin time 6.63 0.24 6 6.88 0.17 4 6.8 0.3 6 6.85 0.19 6 Seconds
Activated partial thromboplastin time 13.12 0.82 6 12.9 0.66 4 13.83 0.81 6 13.33 0.83 6 Seconds
Fibrinogen 270.2 47.3 6 312.5 47.5 4 282 44.6 6 259.8 56.7 6 Mg/dL
Females Erythrocytes
Red blood cells 6.562 0.322 6 6.788 0.297 4 6.49 0.417 6 6.59 0.344 6 M/ul
Hemoglobin 14.62 0.8 6 15.43 0.77 4 14.12 1.52 6 14.7 0.79 6 g/L
Hematocrit 45.15 2.42 6 46.98 2.33 4 43.78 3.88 6 45.22 2.26 6 %
Mean corpuscular volume 68.82 2.46 6 69.2 1.83 4 67.4 2.3 6 68.63 1.52 6 fL
Mean corpuscular volume hemoglobin 22.3 0.58 6 22.75 0.83 4 21.73 1.12 6 22.32 0.61 6 Pg
Mean corpuscular hemoglobin concentration 32.4 0.41 6 32.85 0.31 4 32.17 0.65 6 32.55 0.21 6 g/dL
Reticulocytes 32.4 15.63 6 41.9 19.22 4 34.42 14.98 6 25.3 11.84 6 109/L
Leukocytes
White blood cells 8.123 1.412 6 8.54 1.517 4 8.418 2.205 6 8.655 1.246 6 K/uL
Neutrophils 4.873 1.151 6 4.855 1.139 4 4.88 1.404 6 5.457 0.986 6 K/uL
Lymphocytes 2.482 0.62 6 2.793 0.381 4 2.578 0.459 6 2.482 0.213 6 K/uL
Monocytes 0.473 0.079 6 0.513 0.131 4 0.505 0.185 6 0.353 0.119 6 K/uL
Eosinophils 0.15 0.14 6 0.138 0.019 4 0.313 0.324 6 0.197 0.072 6 K/uL
Basophils 0.093 0.047 6 0.148 0.038 4 0.08 0.029 6 0.102 0.014 6 K/uL
Thrombocytes
platelets 358.8 83 6 350.5 81.3 4 319.2 53.1 6 356.7 49.3 6 K/uL
Mean platelet volume 13.23 2.08 6 13.13 1.27 4 13.43 1.24 6 12.85 1.05 6 fL
Prothrombin time 6.9 0.32 6 7.03 0.25 4 6.73 0.36 6 6.97 0.34 6 Seconds
Activated partial thromboplastin time 13.42 0.65 6 13.4 0.41 4 13.37 0.44 6 13.12 0.37 6 Seconds
Fibrinogen 227 54.8 6 225.8 90.2 4 219.2 42.6 6 205.8 35.3 6 mg/dL
Male and female dogs received indicated doses of α-TEA lysine salt daily for 28 days. Ten days before the treatment start, blood was collected from 6 dogs
(0, 300, 1500 mg/kg treatment groups) or 4 dogs (100 mg/kg treatment group) and analyzed for blood cells and coagulation parameters
Guerrouahen et al. BMC Cancer  (2016) 16:199 Page 7 of 16
Table 4 Mean blood cells and coagulation parameters in dogs 29 days after the start date
Vehicle 100 mg/kg 300 mg/kg 1500 mg/kg Unit
Mean SD N Mean SD N Mean SD N Mean SD N
Males Erythrocytes
Red blood cells 6.238 0.841 4 6.438 0.598 4 6.21 0.143 4 6.418 0.437 4 M/ul
Hemoglobin 14.55 1.91 4 14.55 1.1 4 6.21 0.143 4 6.418 0.437 4 g/L
Hematocrit 42.1 6.09 4 42.18 3.27 4 41.05 1.04 4 41.7 2.79 4 %
Mean corpuscular volume 67.45 1.1 4 65.63 1.51 4 66.08 2.16 4 65 1.75 4 fL
Mean corpuscular hemoglobin 23.35 0.24 4 22.68 0.59 4 22.9 0.64 4 22.73 0.7 4 pg
Mean corpuscular hemoglobin concentration 34.6 0.47 4 34.6 0.37 4 34.63 0.33 4 34.9 0.51 4 g/dL
Reticulocytes 42.73 11.31 4 58.65 15.92 4 46 11.97 4 24.55 3.67 4 109/L
Leukocytes
White blood cells 7.438 0.919 4 9.23 1.25 4 12.23 3.277 4 11.91 3.574 4 K/uL
Neutrophils 4.183 0.937 4 4.805 0.658 4 7.438 3.162 4 7.193 2.464 4 K/uL
Lymphocytes 2.593 0.442 4 3.438 0.597 4 3.56 0.326 4 3.655 0.792 4 K/uL
Monocytes 0.43 0.153 4 0.683 0.089 4 0.825 0.26 4 0.565 0.14 4 K/uL
Eosinophils 0.095 0.039 4 0.178 0.055 4 0.223 0.101 4 0.388 0.328 4 K/uL
Basophils 0.098 0.078 4 0.1 0.018 4 0.138 0.038 4 0.08 0.026 4 K/uL
Thrombocytes
platelets 259.8 64 4 281.8 44.7 4 369.5 87.3 4 262.3 75.2 4 K/uL
Mean platelet volume 10.95 1.11 4 9.88 0.8 4 9 0.87 4 8.6 0.77 4 fL
Protrombin time 6.78 0.05 4 7.08 0.19 4 6.85 0.17 4 6.9 0.24 4 Seconds
Activated partial thromboplastin time 12.68 1.16 4 12.7 0.84 4 13.5 0.88 4 13.05 1.28 4 Seconds
Fibrinogen 254.5 42.7 4 288.5 18.9 4 289.5 85.4 4 414.5 89.9 4 mg/dL
Females Erythrocytes
Red blood cells 6.33 0.241 4 6.895 0.563 4 6.72 0.306 4 6.773 0.383 4 M/ul
Hemoglobin 14.85 1 4 16.43 1.7 4 15.55 1.1 4 15.78 0.8 4 g/L
Hematocrit 43.33 3.14 4 47.68 4.73 4 45.48 3.24 4 45.98 2.05 4 %
Mean corpuscular volume 68.33 2.53 4 69.1 1.14 4 67.83 3.07 4 67.88 1.6 4 fL
Mean corpuscular volume hemoglobin 23.45 0.71 4 23.83 0.55 4 23.15 1 4 23.3 0.55 4 pg
Mean corpuscular hemoglobin concentration 34.25 0.47 4 69.3 23.65 4 72.85 24.88 4 45.75 23.65 4 g/dL
Reticulocytes 34.25 0.47 4 34.5 0.24 4 34.23 0.35 4 34.3 0.46 4 109/L
Leukocytes
White blood cells 8.81 3.586 4 9.75 2.4 4 9.743 1.237 4 13.31 1.721 4 K/uL
Neutrophils 5.293 3.009 4 4.928 1.273 4 5.32 1.312 4 8.193 1.654 4 K/uL
Lymphocytes 2.693 0.318 4 3.575 0.702 4 3.358 0.543 4 3.985 0.625 4 K/uL
Monocytes 0.548 0.218 4 0.495 0.071 4 0.648 0.083 4 0.665 0.281 4 K/uL
Eosinophils 0.163 0.111 4 0.505 0.467 4 0.273 0.1 4 0.3 0.124 4 K/uL
Basophils 0.078 0.022 4 0.175 0.027 4 0.105 0.019 4 0.123 0.051 4 K/uL
Thrombocytes
platelets 275.8 62.7 4 301.3 31.9 4 294.3 79 4 340 72.2 4 K/uL
Mean platelet volume 13.03 2.23 4 10.45 0.79 4 10.85 0.97 4 9.75 0.71 4 fL
Prothrombin time 7.1 0.18 4 7.18 0.15 4 6.8 0.22 4 6.93 0.19 4 Seconds
Activated partial thromboplastin time 12.23 0.72 4 12.68 0.92 4 13.48 0.4 4 12.45 0.47 4 Seconds
Fibrinogen 206 11.1 4 178.5 16.3 4 251.5 68.3 4 275.8 58.8 4 mg/dL
Male and female dogs received indicated doses of α-TEA lysine salt daily for 28 days. After 28 daily treatments, blood was collected from 4 dogs per treatment
group and analyzed for blood cells and coagulation parameters
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Table 5 Mean blood cells and coagulation parameters in dogs at the end of the recovery period (Day 57)
Vehicle 300 mg/kg 1500 mg/kg Unit
Mean N Mean N Mean N
Males Erythrocytes
Red blood cells 5.975 2 6.13 2 6.115 2 M/ul
Hemoglobin 14 2 14.2 2 14.15 2 g/L
Hematocrit 40 2 40.7 2 40.65 2 %
Mean corpuscular volume 67 2 6.35 2 66.7 2 fL
Mean corpuscular hemoglobin 23.4 2 23.15 2 23.2 2 pg
Mean corpuscular hemoglobin concentration 34.9 2 34.85 2 34.8 2 g/dL
Reticulocytes 34.15 2 78.3 2 59.92 2 109/L
Leukocytes
White blood cells 8.705 2 8.025 2 10.37 2 K/uL
Neutrophils 5.275 2 4.53 2 6.14 2 K/uL
Lymphocytes 2.7 2 2.645 2 3.055 2 K/uL
Monocytes 0.34 2 0.225 2 0.385 2 K/uL
Eosinophils 0.21 2 0.225 2 0.385 2 K/uL
Basophils 0.125 2 0.125 2 0.125 2 K/uL
Thrombocytes
platelets 229 2 290.5 2 310 2 K/uL
Mean platelet volume 11.7 2 9.65 2 9.55 2 fL
Protrombin time 7.05 2 7.15 2 7.15 2 Seconds
Activated partial thromboplastin time 13.05 2 13.75 2 12.65 2 Seconds
Fibrinogen mg/dL
Females Erythrocytes
Red blood cells 7.41 2 6.775 2 6.455 2 M/ul
Hemoglobin 17.25 2 15.7 2 15.05 2 g/L
Hematocrit 49.65 2 44.75 2 43.25 2 %
Mean corpuscular volume 66.95 2 66 2 66.8 2 fL
Mean corpuscular volume hemoglobin 23.3 2 23.15 2 23.3 2 pg
Mean corpuscular hemoglobin concentration 34.8 2 35.1 2 34.85 2 g/dL
Reticulocytes 69.4 2 68.25 2 52.3 2 109/L
Leukocytes
White blood cells 8.79 2 7.2 2 8.01 2 K/uL
Neutrophils 4.925 2 3.895 2 4.915 2 K/uL
Lymphocytes 2.87 2 2.785 2 2.475 2 K/uL
Monocytes 0.34 2 0.215 2 0.275 2 K/uL
Eosinophils 0445 2 0.16 2 0.2 2 K/uL
Basophils 0.165 2 0.11 2 0.11 2 K/uL
Thrombocytes
platelets 239.5 2 273 2 274.5 2 K/uL
Mean platelet volume 11.3 2 11.2 2 10 2 fL
Prothrombin time 6.7 2 7.35 2 6.8 2 Seconds
Activated partial thromboplastin time 12.6 2 12.3 2 12.7 2 Seconds
Fibrinogen 291 2 151.5 2 201.5 2 mg/dL
Male and female dogs received indicated doses of α-TEA lysine salt daily for 28 days. After 28 daily treatments, blood was collected from 2 dogs per treatment
group and analyzed for blood cells and coagulation parameters
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Table 6 Mean serum chemistry parameters in dogs 10 days prior to treatment
Vehicle 100 mg/kg 300 mg/kg 1500 mg/kg Unit
Mean SD N Mean SD N Mean SD N Mean SD N
Males Alanine transaminase (ALT) 58.2 47.5 6 55.8 42.2 4 37.7 5.4 6 36.8 15.2 6 U/L
Aspartate transaminase (AST) 27.3 2.1 6 29.8 5.4 4 32.5 3.8 6 29.7 3.7 8 U/L
Alkaline phosphatase (ALKP) 91.2 20.5 6 109.8 39.9 4 93.8 21.7 6 128.7 40.1 6 U/L
Lactate deshydrogenase (LDH) 75.3 24.7 6 71.3 14.4 4 76 13.8 6 67.5 24.5 6 U/L
Total bilirubin (TBILI) 0 0 6 0 0 4 0 0 0 0 0 6 mg/dL
Gamma-Glutamyl transferase (GGT) 0 0 6 0 0 4 0 0 6 0 0 6 U/L
Creatine phosphokinase (CK) 0 0 6 0 0 4 0 0 4 0 0 6 U/L
Sodium (Na) 146 1.5 6 145.5 1 4 146.2 1.3 6 146.7 0.8 6 mmol/L
Potassium (K) 4.65 0.19 6 4.65 0.17 4 113.3 1 6 113 1.1 6 mmol/L
Chloride (CL) 113.5 1.5 6 113.3 1 4 113 1.1 6 113.5 2.4 6 mmol/L
Calcium (CA) 10.13 0.19 6 10.28 0.15 4 10.43 0.3 6 10.53 0.45 0 mg/dL
Inorganic phosphorus (PHOS) 5.43 0.77 6 5.98 0.7 4 5.23 0.38 6 5.3 0.45 6 mg/dL
Blood urea nitrogen (BUN) 14.2 0.8 6 14.5 0.6 4 17 2.7 6 16 2.1 6 mg/dL
Creatinine (CREA) 0.63 0.12 6 0.58 0.05 4 0.6 0 6 0.67 0.08 6 mg/dL
Glucose (GLU) 97.3 3.5 5 91.3 8.3 4 92.3 7.4 6 96 8.9 6 mg/dL
Total protein (TPRO) 4.75 0.24 6 4.98 0.29 4 4.9 0.14 6 4.87 0.26 6 g/dL
Albumin (ALB) 2.88 0.17 6 2.93 0.26 4 2.92 0.12 6 2.83 0.28 6 g/dL
Globulin (GLOB) 1.87 0.18 6 2.05 0.13 4 1.98 0.04 6 2.03 0.23 6 g/dL
Albumin/Globulin ratio (A/G) 1.555 0.165 6 1.431 0.155 4 1.471 0.051 6 1.415 0.249 6 Ratio
Cholesterol (CHOL) 168.3 48.5 6 160.8 9.3 4 150.5 31.5 6 163.8 24 6 mg/dL
Triglycerides (TRIG) 37.3 8.2 6 38.3 5.9 4 36 4 6 40.2 5 6 mg/dL
Females Alanine transaminase (ALT) 31.8 6.6 6 32.8 7.4 4 30.3 4.1 6 37.5 16.3 6 U/L
Aspartate transaminase (AST) 29.3 4.1 6 31.8 11.2 4 27.5 3.4 6 28.3 3.7 6 U/L
Alkaline phosphatase (ALKP) 100 32 6 83.8 18.3 4 95.7 25.5 6 75.3 13.7 6 U/L
Lactate deshydrogenase (LDH) 60.3 18.1 6 65.3 25.1 4 52.2 15.4 6 62.2 21.8 6 U/L
Total bilirubin (TBILI) 0.02 0.04 6 0 0 4 0 0 6 0 0 6 mg/dL
Gamma-Glutamyl transferase (GGT) 0 0 6 0 0 4 0 0 6 0 0 6 U/L
Creatine phosphokinase (CK) 165.7 37.4 6 161.5 73.7 4 141 30.1 6 142 43.6 6 U/L
Sodium (Na) 146.8 1.5 6 147.3 1.7 4 146.7 1 6 147.3 0.8 6 mmol/L
Potassium (K) 4.48 0.26 6 4.48 0.05 4 4.43 0.31 6 4.43 0.21 6 mmol/L
Chloride (CL) 114.2 2.1 6 116 2.2 4 114.7 2.9 6 115 1.3 6 mmol/L
Calcium (CA) 10.48 0.26 6 10.58 0.21 4 10.95 0.27 6 10.82 0.31 6 mg/dL
Inorganic phosphorus (PHOS) 5.3 0.23 6 4.83 0.31 4 5.35 0.55 6 5.17 0.5 6 mg/dL
Blood urea nitrogen (BUN) 15.2 2.3 6 13.3 1 4 14.2 2.6 6 14 3 6 mg/dL
Creatinine (CREA) 0.57 0.05 6 0.6 0 4 0.58 0.08 6 0.65 0.08 6 mg/dL
Glucose (GLU) 99.3 5 6 99.3 7.5 4 99.7 7.4 6 94.5 7 6 mg/dL
Total protein (TPRO) 4.85 0.27 6 5 0.28 4 4.8 0.14 6 5.13 0.16 6 g/dL
Albumin (ALB) 2.95 0.26 6 3.1 0.14 4 2.95 0.18 6 3.13 0.16 4 g/dL
Globulin (GLOB) 1.9 0.09 6 1.9 0.18 4 1.85 0.14 6 2 0 6 g/dL
Albumin/Globulin ratio (A/G) 1.556 0.157 6 162.3 10.5 4 1.607 0.21 6 1.567 0.082 6 Ratio
Cholesterol (CHOL) 160 20.2 6 162.3 10.5 4 142.3 11.3 6 158.2 33 6 mg/dL
Triglycerides (TRIG) 37.3 3.8 6 36 14.1 4 34 4.8 6 46.3 10.4 6 mg/dL
Male and female dogs received indicated doses of α-TEA lysine salt daily for 28 days. Ten days before the treatment start, blood was collected from 6 dogs per
treatment group (0, 300, 1500 mg/kg) or 4 dogs (100 mg/mL) and analyzed for serum chemistry parameters
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Table 7 Mean serum chemistry parameters 29 days after the start date in male dogs
Vehicle 100 mg/kg 300 mg/kg 1500 mg/kg Unit
Mean SD N Mean SD N Mean SD N Mean SD N
Males Alanine transaminase (ALT) 33.5 9.9 4 32 8.6 4 37.3 6.8 4 51 25.9 4 U/L
Aspartate transaminase (AST) 34.8 3.2 4 36.5 5.7 4 46 8.8 4 49.8 5.9 4 U/L
Alkaline phosphatase (ALKP) 96 24.4 4 104.3 37.1 4 116 71.9 4 227 315.9 4 U/L
Lactate deshydrogenase (LDH) 57.8 6.4 4 61 18.7 4 70 21.8 4 55 18.9 4 U/L
Total bilirubin (TBILI) 0.03 0.05 4 0.03 0.05 4 0.03 0.05 4 0 0 4 mg/dL
Gamma-Glutamyl transferase (GGT) 0 0 4 0 0 4 0 0 4 0 0 4 U/L
Creatine phosphokinase (CK) 246.3 79.8 4 185.3 61.2 4 272.3 145.6 4 133 29.1 4 U/L
Sodium (Na) 148.5 1.3 4 148 0.8 4 147.8 0.5 4 148 1.4 4 mmol/L
Potassium (K) 4.35 0.31 4 4.5 0.26 4 4.08 0.32 4 4.48 0.21 4 mmol/L
Chloride (CL) 115.8 1 4 115 0.8 4 115 1.3 4 118.8 0.5 4 mmol/L
Calcium (CA) 10.83 0.25 4 10.88 0.33 4 11.05 0.13 4 10.35 0.29 4 mg/dL
Inorganic phosphorus (PHOS) 5.13 0.75 4 5.45 0.29 4 4.68 0.26 4 3.98 0.32 4 mg/dL
Blood urea nitrogen (BUN) 18.3 2.1 4 18.8 3.3 4 19.3 1.9 4 24.3 1.7 4 mg/dL
Creatinine (CREA) 0.6 0.14 4 0.6 0 4 0.58 0.1 4 0.55 0.08 4 mg/dL
Glucose (GLU) 102.5 4 4 96.3 9 4 96.8 11.2 4 80.8 8.4 4 mg/dL
Total protein (TPRO) 5.25 0.3 4 5.38 0.28 4 5.38 0.24 4 4.45 0.42 4 g/dL
Albumin (ALB) 3.33 0.26 4 3.23 0.29 4 3.18 0.21 4 2.45 0.1 4 g/dL
Globulin (GLOB) 1.93 0.1 4 2.15 0.06 4 2.2 0.14 4 2 0.34 4 g/dL
Albumin/Globulin ratio (A/G) 1.729 0.141 4 1.502 0.152 4 1.448 0.14 4 1.247 0.184 4 Ratio
Cholesterol (CHOL) 168.8 35.4 4 176 28 4 152.3 19.4 4 104.5 183.4 4 mg/dL
Triglycerides (TRIG) 34 8.1 4 41.3 9.7 4 33.3 5.6 4 45.5 14.3 4 mg/dL
Females Alanine transaminase (ALT) 27.3 5.1 4 26.3 1.9 4 35.8 10.2 4 45.5 20.9 4 U/L
Aspartate transaminase (AST) 29 4.7 4 36.3 5.3 4 31.5 3.1 4 45.8 19.5 4 U/L
Alkaline phosphatase (ALKP) 98.8 12.4 4 78.8 22.5 4 178 131.5 4 251.3 211.2 4 U/L
Lactate deshydrogenase (LDH) 82.3 25.8 4 74 19.8 4 69.5 5.9 4 73 19.5 4 U/L
Total bilirubin (TBILI) 0.03 0.05 4 0.05 0.06 4 0.03 0.05 4 0.03 0.05 4 mg/dL
Gamma-Glutamyl transferase (GGT) 0 0 4 0.3 0.5 4 0 0 4 0 0 4 U/L
Creatine phosphokinase (CK) 162.8 54.3 4 198.8 44.1 4 162.3 40.6 4 147.3 47.6 4 U/L
Sodium (Na) 147.8 1 4 148.5 1.9 4 148.5 0.6 4 148.3 1 4 mmol/L
Potassium (K) 4.4 0.34 4 4.53 0.17 4 4.38 0.31 4 4.65 0.34 4 mmol/L
Chloride (CL) 114.5 1.7 4 115.5 1 4 115.5 1 4 117.8 2.8 4 mmol/L
Calcium (CA) 10.7 0.35 4 11.05 0.38 4 11.05 0.37 4 10.25 0.84 4 mg/dL
Inorganic phosphorus (PHOS) 5.03 0.54 4 4.25 0.9 4 4.4 0.47 4 4.35 0.58 4 mg/dL
Blood urea nitrogen (BUN) 17.5 2.4 4 14.5 1.3 4 18.5 1.3 4 23.5 7.9 4 mg/dL
Creatinine (CREA) 0.5 0.08 4 0.58 0.1 4 0.53 0.1 4 0.63 0.05 4 mg/dL
Glucose (GLU) 103.3 4.8 4 102.8 11.5 4 108.8 7.8 4 84.8 2.1 4 mg/dL
Total protein (TPRO) 5.28 0.17 4 5.35 0.31 4 5.3 0.22 4 4.65 0.3 4 g/dL
Albumin (ALB) 3.35 0.17 4 3.38 0.25 4 3.35 0.19 4 2.8 0.22 4 g/dL
Globulin (GLOB) 1.93 0.1 4 1.98 0.1 4 1.95 0.17 4 1.85 0.13 4 g/dL
Albumin/Globulin ration (A/G) 1.745 0.142 4 1.71 0.109 4 1.729 0.191 4 1.516 0.118 4 Ratio
Cholesterol (CHOL) 167.5 24.6 4 179 22.4 4 147.3 10.6 4 98.3 13 4 mg/dL
Triglycerides (TRIG) 40 9.8 4 42 8.8 4 43.5 5.8 4 50 8.3 4 mg/dL
Male dogs received indicated doses of α-TEA lysine salt daily for 28 days. After 28 daily treatments, blood was collected from 4 dogs per treatment group
and analyzed
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Table 8 Mean serum chemistry parameters in dogs at the end of the recovery period (Day 57)
Vehicle 300 mg/kg 1500 mg/kg Unit
Mean N Mean N Mean N
Males Alanine transaminase (ALT) 33 2 36.5 2 33 2 U/L
Aspartate transaminase (AST) 31 2 30.5 2 33 2 U/L
Alkaline phosphatase (ALKP) 81.5 2 66 2 95 2 U/L
Lactate deshydrogenase (LDH) 36 2 50 2 45.5 2 U/L
Total bilirubin (TBILI) 0.05 2 0.05 2 0.1 2 mg/dl
Gamma-Glutamyl transferase (GGT) 0 2 1 2 0 2 U/L
Creatine phosphokinase (CK) 119 2 142.5 2 169 2 U/L
Sodium (Na) 147.5 2 146.5 2 148.5 2 mmol/L
Potassium (K) 4.3 2 4.6 2 4.4 2 mmol/L
Chloride (CL) 116 2 115 2 116.5 2 mmol/L
Calcium (CA) 10.65 2 10.45 2 10.55 2 mg/dL
Inorganic phosphorus (PHOS) 5.15 2 5.1 2 5.3 2 mg/dL
Blood urea nitrogen (BUN) 13.5 2 15.5 2 21 2 mg/dL
Creatinine (CREA) 0.65 2 0.6 2 0.7 2 mg/dL
Glucose (GLU) 99 2 99.5 2 96 2 mg/dL
Total protein (TPRO) 5.3 2 5.15 2 5.4 2 g/dL
Albumin (ALB) 3 2 2.9 2 2.95 2 g/dL
Globulin (GLOB) 2.3 2 2.25 2 2.45 2 g/dL
Albumin/Globulin ratio (A/G) 1.314 2 1.289 2 1.219 2 Ratio
Cholesterol (CHOL) 149 2 154 2 163.5 2 mg/dL
Triglycerides (TRIG) 24 2 24 2 41 2 mg/dL
Females Alanine transaminase (ALT) 22.5 2 31 2 27.5 2 U/L
Aspartate transaminase (AST) 33 2 29 2 26.5 2 U/L
Alkaline phosphatase (ALKP) 73 2 63.5 2 50 2 U/L
Lactate deshydrogenase (LDH) 52 2 49.5 2 47 2 U/L
Total bilirubin (TBILI) 0.1 2 0.1 2 0.1 2 mg/dL
Gamma-Glutamyl transferase (GGT) 0 2 0 2 0 0 U/L
Creatine phosphokinase (CK) 154.5 2 146 2 120 2 U/L
Sodium (Na) 146.5 2 146.5 2 147 2 mmol/L
Potassium (K) 4.5 2 4.5 2 4.1 2 mmol/L
Chloride (CL) 115.5 2 115.5 2 116.5 2 mmol/L
Calcium (CA) 10.95 2 10.65 2 10.5 2 mg/dL
Inorganic phosphorus (PHOS) 5.15 2 4.95 2 4.5 2 mg/dL
Blood urea nitrogen (BUN) 15.5 2 13.5 2 14.5 2 mg/dL
Creatinine (CREA) 0.65 2 0.7 2 0.65 2 mg/dL
Glucose (GLU) 103.5 2 101.5 2 100 2 mg/dL
Total protein (TPRO) 5.7 2 5.15 2 5.25 2 g/dL
Albumin (ALB) 3.3 2 3 2 3.1 2 g/dL
Globulin (GLOB) 2.4 2 2.15 2 2.15 2 g/dL
Albumin/Globulin ratio (A/G) 1.377 2 1.395 2 1.444 2 Ratio
Cholesterol (CHOL) 190.5 2 152 2 161 2 mg/dL
Triglycerides (TRIG) 29.5 2 30.5 2 32 2 mg/dL
Male and female dogs received indicated doses of α-TEA lysine salt daily for 28 days. At the end of the recovery period, on day 57, blood was collected from 2
dogs per treatment group and analyzed
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(BUN), and mean aspartate aminotransferase activity (AST)
values for the 1500 mg/kg males group were statistically
higher compared to the controls. Although not statistically
different, the mean CL, mean BUN, and mean AST values
for the 1500 mg/kg females were minimally higher com-
pared to the controls. The mean total protein concentration
(TPRO), mean albumin (ALB) concentration, mean albu-
min to globulin ratio (A/G), and mean cholesterol (CHOL)
concentration values for the 1500 mg/kg females were sta-
tistically lower compared to the controls. Although not
shown to be statistically different, the mean glucose con-
centration (GLU) value for the 1500 mg/kg females group
was lower compared to the controls (Tables 6 and 7). At
Day 57 (Table 8), the mean BUN concentration value for
the 300 mg/kg and 1500 mg/kg males groups was higher
compared to the controls. This difference was attributed to
the previous anorexia seen in the 1500 mg/kg males group,
but was not of such a magnitude as to be considered an
indication of renal toxicity. No urinalysis changes were
reported at the highest dose (1500 mg/kg).
Histology of major organs
Dogs were euthanized the day following the end of dos-
ing period or following a 28-day recovery period (day
57) by an overdose of sodium pentobarbital followed by
exsanguination. A necropsy with tissue collection was
conducted and included examination of the carcass and
muscular/skeletal system, orifices, cranial cavity and ex-
ternal surface of the brain, neck, thoracic, abdominal
and pelvic cavities associated with their organs. There
were few and minimal α-TEA-related histomorphologic
or organ weight changes observed at the end of dose ad-
ministration in the adrenal glands (1500 mg/kg females),
duodenum (1500 mg/kg males), jejunum (100 and
1500 mg/kg males and 1500 mg/kg females), kidney,
liver (1500 mg/kg, male), and thymus (300 and 1500 mg/
kg males and 100 and 1500 mg/kg females). These find-
ings were considered to be incidental. No α-TEA related
macroscopic changes were observed at the end of dose ad-
ministration or recovery phase, and there were no changes
in organ weight. Interestingly, α-TEA-related histomor-
phologic changes were noted at 1500 mg/kg on Day 29 in
the duodenum (mild, diffuse villous atrophy) at 1500 mg/
kg, jejunum (minimal, focal or multifocal dilation of a
crypt) at all dose levels, kidney (mild, diffuse, bilateral
vacuolation of the epithelium lining the proximal tubules)
at 1500 mg/kg, and liver (minimal, multifocal hepatocellu-
lar necrosis with minimal, multifocal sub-acute inflamma-
tion and moderate, diffuse vacuolation of hepatocytes) at
1500 mg/kg. At the end of recovery period, minimal focal
dilation of jejunal crypt and moderate diffuse vacuolation
of hepatocytes was present at 1500 mg/kg and mild diffuse
depletion of lymphocytes of the thymic cortex was noted
at 300 mg/kg.
Toxicokinetics parameters
Samples of blood were collected from the jugular vein of
all animals at 1, 2, 4, 8, 24 h at day 1 and day 28 when
animals received the test article. The validated LC-MS/MS
method was used to analyze plasma α-TEA concentration.
Mean plasma α-TEA concentrations in all samples ob-
tained at 8 h post-dose from control animals on Day 1
were below the lower limit of quantitation (50.0 ng/mL),
indicating no exposure of treated animals to α-TEA prior
to dosing. As shown in Table 9, the mean Tmax ranged
from 16.0 to 24.0 h on Day 1 and from 6.3 to 10.7 h on
Day 28. Elimination half-life values were not calculated or
not reported on Days 1 and 28 due to insufficient data
Table 9 Mean toxicokinetic parameters at day 1 and 28-day dosing of α-TEA lysine salt
Day Group α-TEA Dose (mg/kg) Sex Tmax (hr) T1/2 (hr) Cmax (ng/mL) AUC0-24 (hr*ng/ml)
1 2 100 Male 24 NC 20200 335000
1 2 100 Female 20 NC 23900 35100
1 3 300 Male 16 NC 41000 718000
1 3 300 Female 18.7 NC 48600 72900
1 4 1500 Male 24 NC 69100 1170000
1 4 1500 Female 16 NC 76900 1240000
28 2 100 Male 6.3 NC 148000 3290000
28 2 100 Female 7 NC 16000 3620000
28 3 300 Male 7.3 NC 211000 4740000
28 3 300 Female 8 NC 212000 4670000
29 4 1500 Male 8 NC 206000 4580000
28 4 1500 Female 10.7 NC 192000 4210000
Blood were collected collected at 1, 2, 4, 8, and 24 h following the first α-TEA administration and 2, 8, 24, 72, and 168 h following the last administration (day 28).
The validated method (high performance liquid chromatography with mass spectrometric detection) was used to analyse plasma α-TEA concentration. Cmax, Tmax,
T1/2, AUC were determined using WinNonlin Version 6.2 software system
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points for the elimination phase. On Days 1 and 28, in-
creases in Cmax and AUC0-24 were less than proportional
for both males and females. On the first day of administra-
tion, for a 15-fold increase in dose from 100 to 1500 mg/
kg, Cmax values increased 3.42-fold for males and 3.22-fold
for females and AUC0-24 values increased 3.49-fold for
males and 3.53-fold for females. On Day 28, α-TEA expos-
ure was similar at 300 and 1500 mg/kg, this reflects a sat-
uration phenomenon at 300 mg/kg dose level and above.
For a 3-fold increase in dose from 100 to 300 mg/kg, Cmax
increased 1.43-fold for males and 1.33-fold for females
and AUC0-24 increased 1.44-fold for males and 1.29-fold
for females. Cmax and AUC0-24 values were similar be-
tween males and females. The ratio of Cmax for males to
Cmax for females at each dose level ranged from 0.84 to
0.90 on Day 1 and from 0.93 to 1.07 on Day 28. The ratio
of AUC0-24 for males to AUC0-24 for females at each dose
level ranged from 0.94 to 0.98 on Day 1 and from 0.91 to
Fig. 5 Mean plasma α-TEA lysine salt concentration versus time at day 1 for male and female dogs. Male dogs received indicated doses of α-TEA
lysine salt on day 1. Plots of α-TEA plasma concentration versus time are presented
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1.09 on Day 28. The AUC ratios for α-TEA LS (ratio of
AUC0-24 on Day 28 to the AUC0-24 on Day 1) was 9.82 for
males and 10.31 for females at 100 mg/kg), 6.60 for males
and 6.41 for females at 300 mg/kg, and 3.91 for males and
3.40 for females at 1500 mg/kg. Plots of α-TEA plasma
concentration versus time are presented in Figs. 5 and 6
for Day 1 and Day 28, respectively. Exposure of animals
on Day 28 was higher than exposure on Day 1, indicating
accumulation of α-TEA with multiple dosing. The extent
of accumulation was greatest at the low-dose level and
decreased with increasing dose, presumably due to satur-
ation of exposure at the mid- and high-dose levels. No
sex-specific differences in toxicokinetics values could be
reported.
Discussion
This toxicology and pharmacokinetics study of GMP
grade α-TEA was conducted to support an Investigator
New Drug (IND) application to the FDA to conduct a
first-in-human clinical trial in patients with advanced
Fig. 6 Mean plasma α-TEA lysine salt concentration versus time at day 28 for male and female dogs. Female dogs received indicated doses of
α-TEA lysine salt on day 1. Plots of α-TEA plasma concentration versus time are presented
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cancer based on the immunological and pro-apoptotic
properties of α-TEA. Our results demonstrate that orally
administered α-TEA LS reduces tumor growth and in-
creases overall survival in mice bearing established tumors.
This anti-tumor activity is comparable to that of α-TEA
free acid that we previously reported [11]. However, unlike
α-TEA free acid, which is difficult to manufacture for hu-
man use due to its liquid crystal properties, α-TEA LS is
crystalline in nature and can be delivered in aqueous form
to animals. In the non-rodent dose escalation study, in
which optimal conditions and timing of orally administered
α-TEA LS were assessed, there were no signs of toxicity in
dogs that received daily doses of up to 1500 mg/kg. No
moribundity or mortality was observed at any of the dose
levels tested throughout the treatment period. No gender-
related differences were observed. Minor histomorphologic
alterations were observed at the highest dose but these
changes were mostly reversed at the end of the recovery
period.
Clinical pathology changes were limited to increased
white blood cell (lymphocyte and neutrophil) counts,
and fibrinogen levels at 1500 mg/kg; these changes were
likely related to mild inflammation and/or stress but all
these findings were resolved by the end of recovery
period. Although a full and complete toxicokinetic pro-
file could not be determined from the study, there was
an apparent less than dose proportional increase in AUC
over the duration of the study. The extent of accumulation
was greatest at the low-dose level and decreased with in-
creasing dose, presumably due to saturation of exposure
at the mid- and high-dose levels.
Conclusion
In summary, in this comprehensive examination of the
prolonged use of GMP-grade α-TEA LS in dogs, followed
by a 28-day recovery period, we report absence of any
dose limiting toxicity. Our findings suggest that α-TEA is
safe and tolerated and determined that the highest non-
severely toxic dose (HNSTD) to be 1500 mg/kg. These
findings formed the basis for initiating a first-in-human
clinical trial of α-TEA in patients with advanced cancer,
which is ongoing.
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